Evidence map›Paper›PMID 41078774›Full record

ArticleACS omega2025

How the Universal MSA52 Aptamer Recognizes the SARS-CoV‑2 Spike Protein.

Tadsanee Awang, Firdaus Samsudin, Deanpen Japrung, Peter John Bond, Prapasiri Pongprayoon

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tadsanee AwangDepartment of Chemistry, Faculty of Science, Kasetsart University, Chatuchak, Bangkok 10900, Thailand.
Firdaus SamsudinBioinformatics Institute (BII), Agency for Science, Technology and Research (A*STAR), 30 Biopolis Street, #07-01 Matrix, Singapore 138671, Republic of Singapore.
Deanpen JaprungNational Nanotechnology Center, National Science and Technology Development Agency, Thailand Science Park, Pathum Thani 12120, Thailand.ORCID https://orcid.org/0000-0003-4206-6641
Peter John BondBioinformatics Institute (BII), Agency for Science, Technology and Research (A*STAR), 30 Biopolis Street, #07-01 Matrix, Singapore 138671, Republic of Singapore.ORCID https://orcid.org/0000-0003-2900-098X
Prapasiri PongprayoonDepartment of Chemistry, Faculty of Science, Kasetsart University, Chatuchak, Bangkok 10900, Thailand.ORCID https://orcid.org/0000-0002-1472-8241

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the COVID-19 pandemic. The prominent characteristic of SARS-CoV-2 is the use of a trimeric spike (S) glycoprotein to invade the host cell; therefore, the S protein has become a major drug and vaccine target. Recently, a universal aptamer (MSA52) has been reported to bind to the S protein of seven former variants of concern (VOCs) in both glycan and nonglycan forms. However, no molecular details regarding these interactions are currently available. Thus, in this work, molecular dynamics (MD) simulations were performed to understand the binding of MSA52 to the S protein in both its nonglycosylated (NG) and glycosylated (G) forms. In the NG, MSA52 is inserted between the receptor binding domain (RBD) and the N-terminal domain (NTD), whereas most parts of MSA52 were in contact with the RBD in the G form. This binding is observed to be driven primarily by electrostatic interactions. MSA52 seems to bind more tightly to NG than G. In G, not only protein components but also glycans interact with MSA52. MSA52 targets the RBD like other existing aptamers, but it binds to a conserved region, explaining its ability to recognize seven VOCs. Furthermore, MSA52 can bind both RBD-up and RBD-down conformations, which could be beneficial for the effective prevention of viral infection during different mechanistic stages. The molecular insights obtained here will be useful for the future design of more effective SARS-CoV-2 aptamer-based biosensors.

Identifiers

PMID41078774
PMCPMC12509022

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.